Smith Marvin K, Lesniak Bryson, Baraga Michael G, Kaplan Lee, Jose Jean
UHealth Sports Performance and Wellness Institute, Miami, Florida.
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
Sports Health. 2015 Sep-Oct;7(5):409-14. doi: 10.1177/1941738115585520. Epub 2015 May 5.
The purpose of this study was to determine the efficacy of ultrasound-guided aspiration, fenestration, and injection as a treatment in patients with symptomatic popliteal cysts.
Ultrasound-guided aspiration, fenestration, and injection (UGAFI) is an effective and safe treatment option for symptomatic popliteal cysts.
Retrospective cohort study.
Level 3.
Patients who received a UGAFI of popliteal cysts from 2008 to 2011 were identified. Preaspiration (PA) and follow-up Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores, cyst recurrence, complications, cyst complexity, and size were obtained and compared for statistical significance. UGAFI involved aspiration of fluid through a spinal needle, fenestration of the cyst walls and septations, and injection of 1 mL (40 mg) triamcinolone (Kenalog) and 2 mL 0.5% bupivacaine (Sensorcaine) into the decompressed remnant.
The mean PA WOMAC score (48.55) improved significantly at final follow-up (FFU) to 17.15 (P < 0.0001) for 47 patients. Within the WOMAC subcategories, there was also a significant difference in pain (PA, 10.68; FFU, 3.94; P < 0.0001), stiffness (PA, 4.51; FFU, 1.77; P < 0.0001), and physical function (PA, 31.34; FFU, 12.17; P < 0.0001). There were 6 reaspirations for recurrence (12.7%), and 1 patient underwent unicompartmental knee arthroplasty. There were no infections or other complications.
Significant clinical improvement in patients with symptomatic popliteal cysts can be achieved via UGAFI as the sole treatment.
UGAFI is a safe and effective option as the sole treatment modality for symptomatic popliteal cysts.
本研究的目的是确定超声引导下抽吸、开窗和注射治疗有症状的腘窝囊肿患者的疗效。
超声引导下抽吸、开窗和注射(UGAFI)是治疗有症状腘窝囊肿的一种有效且安全的治疗选择。
回顾性队列研究。
3级。
确定2008年至2011年接受腘窝囊肿UGAFI治疗的患者。获取抽吸前(PA)和随访时的西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分、囊肿复发情况、并发症、囊肿复杂性和大小,并进行统计学显著性比较。UGAFI包括通过脊髓穿刺针抽吸液体、囊肿壁和分隔的开窗,以及向减压后的残余腔内注射1 mL(40 mg)曲安奈德(康宁克通)和2 mL 0.5%布比卡因(耐乐品)。
47例患者的平均PA WOMAC评分(48.55)在末次随访(FFU)时显著改善至17.15(P < 0.0001)。在WOMAC亚类中,疼痛(PA,10.68;FFU,3.94;P < 0.0001)、僵硬(PA,4.51;FFU,1.77;P < 0.0001)和身体功能(PA,31.34;FFU,12.17;P < 0.0001)也有显著差异。有6例因复发进行了再次抽吸(12.7%),1例患者接受了单髁膝关节置换术。无感染或其他并发症。
通过UGAFI作为唯一治疗方法,有症状的腘窝囊肿患者可实现显著的临床改善。
UGAFI作为有症状腘窝囊肿的唯一治疗方式是一种安全有效的选择。